| Summary of Earnings Per Share |
The following table presents earnings per share for the three months ended March 31, 2026, and 2025.
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
March 31,
2026 |
|
|
March 31,
2025 |
|
Basic: |
|
|
|
|
|
|
Net income (loss) allocable to common stockholders |
|
$ |
16,966 |
|
|
$ |
15,041 |
|
Weighted average common shares outstanding |
|
|
21,017,906 |
|
|
|
17,475,058 |
|
Weighted average vested restricted stock units |
|
|
19,148 |
|
|
|
7,763 |
|
Weighted average shares |
|
|
21,037,054 |
|
|
|
17,482,821 |
|
Basic earnings (loss) per common share |
|
$ |
0.81 |
|
|
$ |
0.86 |
|
Diluted: |
|
|
|
|
|
|
Net income (loss) allocable to common stockholders |
|
$ |
16,966 |
|
|
$ |
15,041 |
|
Weighted average common shares outstanding for: |
|
|
|
|
|
|
Basic earnings per common share |
|
|
21,037,054 |
|
|
|
17,482,821 |
|
Dilutive effects of the assumed exercise of stock options |
|
|
103,116 |
|
|
|
62,743 |
|
Dilutive effects of the assumed vesting of restricted stock units |
|
|
121,377 |
|
|
|
112,291 |
|
Dilutive effects of the assumed exercise of ESPP purchases |
|
|
1,617 |
|
|
|
1,738 |
|
Average shares and dilutive potential common shares |
|
|
21,263,164 |
|
|
|
17,659,593 |
|
Diluted earnings (loss) per common share |
|
$ |
0.80 |
|
|
$ |
0.85 |
|
|
| Schedule of Average Shares Not Included In the Computation of Diluted Earnings Per Share |
Average shares not included in the computation of diluted earnings per share because they were antidilutive are shown in the following table as of March 31, 2026, and 2025.
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
March 31,
2026 |
|
|
March 31,
2025 |
|
Stock options |
|
|
325,968 |
|
|
|
237,004 |
|
Restricted stock units |
|
|
63,508 |
|
|
|
74,263 |
|
Total antidilutive shares |
|
|
389,476 |
|
|
|
311,267 |
|
|